



3-15-07

Ifw

PTO/SB/21 (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/553,731-Conf. #4727
	Filing Date	October 18, 2005
	First Named Inventor	Christian Hubschwerlen
	Art Unit	N/A
	Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	Attorney Docket Number	64348(41925)

**ENCLOSURES (Check all that apply)**

<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard
<b>Remarks</b>		

**SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT**

Firm Name	EDWARDS ANGELL PALMER & DODGE LLP		
Signature			
Printed name	Peter F. Corless		
Date	March 13, 2007	Reg. No.	33,860



Application No. (if known): 10/553,731

Attorney Docket No.: 64348(41925)

## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EV888715545US in an envelope addressed to:

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on March 13, 2007  
Date

*Susan M Dillon*

Signature

Susan Dillon

Typed or printed name of person signing Certificate

Registration Number, if applicable

(617) 439-4444

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (42 References) (2 pages)  
Information Disclosure Statement (2 pages)  
Transmittal (1 page)



Docket No.: 64348(41925)  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Christian Hubschwerlen et al.

Application No.: 10/553,731

Confirmation No.: 4727

Filed: October 18, 2005

Art Unit: N/A

For: NOVEL COMPOUNDS HAVING AN  
ANTIBACTERIAL ACTIVITY

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "Documents Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

Applicants submit herewith a copy of the International Search Report of the corresponding International Application.

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).


In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed documents.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 64348(41925).

Dated: March 13, 2007

Respectfully submitted,

By 

Peter F. Corless

Registration No.: 33,860

EDWARDS ANGELL PALMER & DODGE  
LLP

P.O. Box 55874

Boston, Massachusetts 02205

(617) 439-4444

Attorneys/Agents For Applicant



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/553,731-Conf. #4727
				Filing Date	October 18, 2005
				First Named Inventor	Christian Hubschwerlen
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	64348(41925)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US-3,184,462	05/18/1965	Scarborough et al.	
	AB	US-5,250,544	10/05/1993	Lavielle et al.	
	AC	US-5,747,502	05/05/1998	Hanaoka et al.	
	AD	US-6,046,206	04/04/2000	Pamukcu et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	WO 96/39145 A1	12/12/1996	Rhone-Poulenc Rorer Pharmaceuticals Inc.		
	BB	WO 99/10442 A1	01/14/1999	Zeneca Limited		
	BC	WO 99/48461 A2	09/30/1999	Department of the Army		
	BD	WO 00/78748 A1	12/28/2000	Smithkline Beecham P.L.C.		
	BE	WO 01/07432 A2	02/01/2001	Smithkline Beecham P.L.C.		
	BF	WO 01/10842 A2	02/15/2001	Millennium Pharmaceuticals, Inc.		
	BG	WO 01/46150 A2	06/28/2001	Glaxo Group Limited		
	BH	WO 02/08224 A1	01/31/2002	Smithkline Beecham P.L.C.		
	BI	WO 02/40474 A2	05/23/2002	Aventis Pharma S.A.		
	BJ	WO 02/056882 A1	07/25/2002	Smithkline Beecham P.L.C.		
	BK	WO 02/072572 A1	09/19/2002	Aventis Pharma S.A.		
	BL	WO 03/064421 A1	08/07/2003	Glaxo Group Limited		
	BM	WO 03/087098 A1	10/23/2003	Smithkline Beecham P.L.C.		
	BN	WO 2004/002992 A1	01/08/2004	Glaxo Group Limited		
	BO	WO 2004/035569 A2	04/29/2004	Morphochem Aktiengesellschaft Für Kombinatorische Chemie		
	BP	WO 2004/058144 A2	07/15/2004	Glaxo Group Limited		
	BQ	WO 2006/021448 A1	03/02/2006	Morphochem Aktiengesellschaft Für Kombinatorische Chemie		
	BR	JP 61200544 (w/abstract)	09/05/1986	Toyo Ink Mfg. Co.		
	BS	EP 0 042781 B1 (w/abstract)	03/06/1985	Pharmuka Laboratories		
	BT	EP 0 264 883 A2	04/27/1988	Banyu Pharmaceutical Co., Ltd.		
	BU	EP 0 486 022 B1	05/20/1992	Eisai Co., Ltd.		
	BV	EP 0 737 670 B1 (w/abstract)	10/16/1996	Adir et Compagnie		
	BW	DE 102 47 233 A1 (w/abstract)	06/17/2004	Morphochem Aktiengesellschaft Für Kombinatorische Chemie		
	BX	DE 102 56 405 A1 (w/abstract)	06/17/2004	Morphochem Aktiengesellschaft Für Kombinatorische Chemie		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

596561

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/553,731-Conf. #4727
				Filing Date	October 18, 2005
				First Named Inventor	Christian Hubschwerlen
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	64348(41925)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	CA	Chemical Abstract – Wei t al.; "A practical procedure for multisubstituted .beta.-naphthols and their derivatives" Tetrahedron, 59(34), 2003, pp. 6621-6625.		
	CB	Chemical Abstract – Harayama et al.; "Novel synthesis of naphthobenzazepines from N-bromobenzylnaphthylamines by regioselective C-H activation utilizing the intramolecular coordination of an amine to Pd"; Synlett, (8), 2003, pp. 1141-1144.		
	CC	Chemical Abstract – Nagy et al.; "Theoretical and Experimental Study on Ion-Pair Formation and partitioning of organic Salts in Octano/Water and Dichloromethane/Water Systems"; Journal of the America Chemical Society; 122 (28), 2000, pp. 6583-6593.		
	CD	Chemical Abstract – Moehle et al.; "1,2,3,4-Tetrahydroquinolines as substrates for Mannich compounds"; Zeitschrift Fuer Naturforschung, B: Chemical Sciences; 53(7), 1998, pp. 742-752.		
	CE	Chemical Abstract – Mathe-Allainmat et al.; "Synthesis of 2-Amido-2,3-dihydro-1H-phenalene Derivatives as New Conformationally Restricted Ligands for Melanotin Receptors"; Journal of Medicinal Chemistry; 39 (16), 1996, pp. 3089-3095.		
	CF	Chemical Abstract – Iwasaki et al.; "Novel Selective PDE IV Inhibitors as Antiasthmatic Agents. Synthesis and Biological Activities of a Series of 1-Aryl-2,3-bis(hydroxymethyl) naphthalene Lignans"; Journal of Medicinal Chemistry, 39(14), 1996, pp. 2696-2704.		
	CG	Chemical Abstract – Zhang et al.; "Organic reactions in chiral micelles. 7. The structural effects on the asymmetric oxidation of prochiral Sulfides in chiral micelles"; Chinese Journal of Chemistry, (1), 1990, pp. 89-96.		
	CH	Chemical Abstract – Smidkal, Jan; "Synthesis of fagoronine"; Collection of Czechoslovak Chemical Communications; 53(12), 1998, pp. 3184-3192.		
	CI	Chemical Abstract – Fleischhacker et al.; "Heterocyclic fused naphthalene systems from thebaine. 1"; Liebigs Annalen Der Chemie, (5), 1983, pp. 844-851.		
	CJ	Chemical Abstract – Budzikiewicz et al.; "Vincetene, a benzopyrroloisoquinoline alkaloid, from Cynanchum vincetoxicum (L.) Pers. (Asclepiadaceae)"; Liebigs Annalen Der Chemie (8), 1979, pp. 1212-1231.		
	CK	Chemical Abstract – Frost et al.; "Naturally occurring compounds related to phenalenone. V. Synthetic approaches to structures based on 8,9-dihydro-8,8,9-trimethylphenaleno [1,2-b] furan-7-one"; Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry; (19), 1973, pp. 3159-2169.		
	CL	Chemical Abstract – Jorgensen et al.; "Thyroxine analogs. 20. Substituted 1- and 2-naphthyl ethers of 3,5-diiodotyrosine"; Journal of Medicinal Chemistry, 14(11), 1971, pp. 1023-1026.		
	CM	Chemical Abstract – Kasturi et al.; "Reactions of tetrahalo-1,2-benzoquinones. III. Reaction of tetrachloro-1,2-benzoquinone with tetralones and naphthols: pathway to the condensates"; Journal of the Chemical Society [Section] C: Organic, (9), 1970, pp. 1257-1259.		
	CN	Chemical Abstract – Harada et al.; "Structure of pristimerin, a quinonoid triterpene"; Tetrahedron Letters, 1962, pp. 603-607.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--